Teva (TEVA) Pharmaceutical has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma and its wholly owned subsidiary Teva Takeda Yakuhin will be transferred to JKI. The divestment will allow Teva to focus on its innovative medicines business in Japan. Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva presents data from SPACE study
- Notable open interest changes for December 2nd
- Teva put volume heavy and directionally bearish
- Teva Pharmaceutical Strengthens Board with New Appointment
- Teva selloff brings good entry point, says UBS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
